positive in Helicobacter pylori infection
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 to 70 years, of any sex; 2. Clinically evaluated by a physician and scheduled to receive Vonoprazan-Tetracycline (VT) dual therapy for Helicobacter pylori eradication; 3. Willing to participate voluntarily and able to comply with the study procedures.
Exclusion criteria
Exclusion criteria: 1. Long-term use of medications that may affect the gastrointestinal microecology, such as oral probiotics. 2. Previous Helicobacter pylori eradication therapy that included tetracycline. 3. Pregnant or breastfeeding women. 4. Use of medications within 4 weeks prior to treatment that may influence the results, such as bismuth agents, acid suppressants (PPI or P-CAB), or antibiotics. 5. History of gastrointestinal surgery. 6. Presence of other serious diseases that could interfere with the evaluation of this study, such as severe liver disease, pulmonary disease, hematological disorders, endocrine disorders, cardiovascular disease, renal disease, malignant tumors, or alcohol abuse. 7. Concurrent medical conditions that may affect the gastrointestinal microecology. 8. Participation in another drug study within 3 months prior to the use of the study drug. 9. Inability to accurately express subjective symptoms, such as in patients with psychosis or severe psychoneurosis, rendering them unable to cooperate with the study. 10. Other conditions deemed by the investigator as inappropriate for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in fecal 16S rRNA sequencing and metagenomic sequencing before treatment and at various time points after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Detection of antibiotic resistance genes in fecal bacteria; | — |
Countries
China
Contacts
Peking University First Hospital